Pfizer's obesity drug shows potential with monthly dosing after weekly ramp
TL;DR Summary
Mid-stage data from Pfizer’s obesity drug berobenatide (from Metsera) suggest dosing it monthly after an initial weekly period can sustain weight loss through 28 weeks, with up to 12.1% loss in patients who stayed on treatment, though the monthly pace lags Lilly’s Zepbound and competitive clarity remains uncertain.
- Detailed data show Pfizer’s monthly obesity drug continues to show potential statnews.com
- Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial Reuters
- The next goal for weight loss drugs? Fewer injections NBC News
- Pfizer Bets on Weight-Loss Drugs to Power Its Next Decade Bloomberg.com
- Pfizer’s Berobenatide GLP-1 Obesity Data Might Change The Case For Investing In Pfizer (PFE) Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
2 min
vs 3 min read
Condensed
91%
528 → 48 words
Want the full story? Read the original article
Read on statnews.com